Banner C5 Communications Life Sciences IP Summit 2015 Berlin 600x60px
Document › Details

Orexo AB. (8/31/11). "Press Release: Orexo Appoints Carl-Johan Blomberg as New Chief Financial Officer". Uppsala.

Organisation Organisation Orexo AB (OMX Nordic List, Mid Cap: ORX)
  Group Orexo (Group)
Products Product pain drug
  Product 2 anti-inflammatory drug
Persons Person Blomberg, Carl-Johan (Orexo 201109– CFO before Micronic Mydata + Alfa Laval + Procordia + Pharmacia & Upjohn)
  Person 2 Lundström, Anders (Orexo 201102– CEO before Biogen Idec + AstraZeneca + Janssen-Cilag + BMS)

Orexo AB (STO: ORX) appoints Carl-Johan Blomberg as new Chief Financial Officer, effective September 1. Carl-Johan Blomberg will take overall responsibility for the Group's Finance and Administration function, including IR and IT and will be part of the executive management team.

Carl-Johan has many years extensive experience in Finance from various industries, such as engineering, electronics and pharmaceuticals. Most recently he held the position of CFO at Micronic Mydata, and has earlier held Financial Director positions within Alfa-Laval, Procordia and Pharmacia & Upjohn.

"We are very pleased with the recruitment of Carl-Johan as our new CFO. He brings broad experience and will play a key role in the future development of Orexo," says Anders Lundström, President and CEO of Orexo AB.

Contact details:
Anders Lundström, President and CEO, Orexo AB
Tel: +46 706 67 22 66

About Orexo

Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo's registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary Kibion. More information can be found at


Orexo AB (publ) discloses the information provided in this press release pursuant to the Securities Markets Act. The information was provided for public release on August 31, 2011 at 11:15a.m. CET. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence.

Record changed: 2015-08-10


Picture YIP Events China Bio-Pharma Executive Summit Nov 2015 Shanghai 600x60px

More documents for Orexo (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture BIO Deutschland European Business Development Conference 600x60px

» top


Banner C5 Communications Life Sciences IP Summit 2015 Berlin 120x180px Picture IQPC IP Life Sciences Exchange 2015 Frankfurt Germany 120x180px Picture EBD Group BIO Europe 2015 BEU Munich November 120x80px Picture BIO Deutschland European Business Development Conference 120x240px Picture Universal Medica Innovations Days 2015 Paris France October 120x180px Picture LSBC Central European Life Science Investment Conference 2015 120x240px Picture YIP Events China Bio-Pharma Executive Summit Nov 2015 Shanghai 120x180px Picture BioM Munich Biomarker Conference 2015 München Germany December 120x180px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Banner [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px